12,372 trials
Infections, Papillomavirus · Papillomavirus Vaccines
Primary: Number of Seroconverted (SCR) Subjects for Anti-Human Papillomavirus Type 16 (Anti-HPV-16) and Anti-Human Papillomavirus Type 18 (Anti-HPV-18) — 118; 127; 126; 371…
Hereditary Periodic Fevers
Primary: Percentage of Participants With Resolution of Initial Flare and Absence of New Flares up to the End of the Randomized Treatment Epoch (16 Weeks) — 61.29; 6.25; 35.14…
Epilepsy
Primary: Percentage of Subjects With at Least One Adverse Event During the 16-week Treatment Period — 66.1; 66.6 percentage of participants
Familial Amyloid Polyneuropathy · Familial Amyloidosis
Primary: Neurologic Impairment Score + 7 (NIS+7) — 8.2; 26.3; 6.2; 12.5 units on a scale — p=<0.001
Bipolar Depression
Primary: Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — 7.4; 7.9 UNITS ON A SCALE
Cervical Dystonia
Primary: Change From Baseline in Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Total Score at Week 4. — 42.5; 42.4; 31.7; 39.9 units on a scale — p=<0.001
Infections, Streptococcal
Primary: Antibody Concentrations Against Pneumococcal Serotypes (Epoch 001) — 2.78; 3.03; 4.23; 3.87 µg/mL
Primary Immunodeficiency Diseases
Primary: Number of Serious Bacterial Infections Per Person-year of Treatment — 0.080 Serious infections per person-year of tr
Asthma · Wheezing
Primary: Differential Response to the Three Therapies Based on Fixed Threshold Criteria for the Following Asthma Control Measures: Use of Oral Prednisone for Acute Asthma…
Breast Cancer · Drug/Agent Toxicity by Tissue/Organ · Unspecified Adult Solid Tumor, Protocol Specific
Primary: To Determine Whether the Prophylactic Use of a Topical Urea/Lactic Acid Cream Can Decrease the Incidence/Severity of Capecitabine-caused Palmar-plantar…
Hypercholesterolemia
Primary: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT Analysis) — 4.7; -53.5; -51.7 percent change — p=<0.0001
Acute Moderate-to-severe Pain
Primary: Time-weighted Summed Pain Intensity Difference (SPID) Over the 12-hour Study Period (SPID12). — 36.04 units on a scale
Chorioamnionitis
Primary: Treatment Success Defined as Resolution of Fever by 24 Hours Postpartum — 43; 49 Participants — p=1.0
Dry Eye Disease
Primary: Change From Baseline in Patient-Reported Eye Dryness Score to Day 84 — 69.0; 68.3; -30.7; -37.9 units on a scale — p==0.0007
Endothelial Dysfunction
Primary: Percentage Change in Coronary Artery Diameter — 3; 3 % change coronary artery diameter